UAE’s Julphar launches 6-pillar Strategy 2030 to drive sustainable growth

UAE’s Julphar launches 6-pillar Strategy 2030 to drive sustainable growth

Gulf Pharmaceutical Industries (Julphar), one of the leading drugmakers in the UAE, has launched its Strategy 2030 to drive transformation through sustainable growth and deliver enhanced value for all stakeholders.

Strategy 2030 is set to triple Julphar’s revenues via six central growth pillars, including ‘Maximizing Revenue from Current Product Portfolio,’ ‘New Product Launches,’ ‘Geographical Expansions,’ ‘Strategic Business Initiatives,’ ‘Advanced Specialty Products Initiative’, and ‘In-Organic Growth Initiatives’.

The new growth strategy embodies Julphar’s ambition to be the top pharmaceutical company in the MENA region, with first-to-market products and value-adding medicine. Strategy 2030 is driven by adopting new, cutting-edge technologies across all of Julphar’s manufacturing plants.

Julphar has been working to maximize revenue from its existing products by growing market share and lowering costs as part of its growth plan framework. Meanwhile, the company is speeding up its efforts to gain Good Manufacturing Practices (GMP) clearances from PICs, ANVISA, the WHO, and the EU in order to expand its portfolio into other strategic locations.

Dr. Essam Mohamed

CEO – Julphar “Setting out our Strategy 2030 today, we are committed to concentrating our efforts and resources on our priority growth platforms and pipeline projects. Despite the enormous challenges and the global pandemic, Julphar achieved one of the most